Harmony Biosciences to Report Q4 and Full-Year 2025 Results
Harmony Biosciences Holdings Inc. (Nasdaq: HRMY) will report its fourth quarter and full-year 2025 financial results on Tuesday, February 24, 2026, before U.S. financial markets open. The company will host a conference call and webcast at 8:30 a.m. Eastern Time on the same day to discuss these results. Investors can access the live and replay webcast via the investor relations section of the company's website.
Public Sector Pension Investment Board Buys 54,605 Shares of Harmony Biosciences Holdings, Inc. $HRMY
The Public Sector Pension Investment Board increased its stake in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 41.6% during the third quarter, purchasing an additional 54,605 shares and bringing its total holdings to 185,803 shares valued at $5.12 million. Other institutional investors have also adjusted their positions in the company, which currently has a market capitalization of $1.98 billion and an average analyst rating of "Moderate Buy." Insider trading activity included sales by the CEO and CFO totaling over $1.1 million in the last quarter.
Harmony Biosciences (NASDAQ:HRMY) Shares Down 5.5% - Time to Sell?
Harmony Biosciences (NASDAQ:HRMY) saw its shares drop 5.5% on Wednesday, with trading volume 27% above average. Despite the dip, analysts maintain a "Moderate Buy" consensus rating with a target price of $45.63. Recent insider sales, including by the CFO and CEO, totaled nearly $2 million, but institutional investors have been increasing their stakes.
Earnings preview: Harmony Biosciences Holdings, Inc. (HRMY) Q4 earnings expected to decline
Harmony Biosciences Holdings, Inc. (HRMY) is expected to announce a year-over-year decline in its fourth-quarter earnings and revenue. Analysts predict a diluted earnings per share of $0.57 and revenue of $169.45 million, reflecting a decrease from the previous year. The company's stock has seen significant price changes recently, including a 13.91% increase in a week and a 10.37% loss over the past four weeks.
Harmony Biosciences Receives FDA Approval for Wakix Label Expansion
Harmony Biosciences announced that its sleep disorder therapy, Wakix (pitolisant), has received FDA approval to treat narcolepsy in children aged six and older. This label expansion broadens the drug's therapeutic potential beyond adults and opens up a significant pediatric market for the company. CEO Jeffrey Dayno expressed a positive outlook, emphasizing plans for further growth and expansion of pitolisant through additional indications and new formulations.
Harmony Bio wins FDA label expansion for Wakix (HRMY:NASDAQ)
Harmony Biosciences received FDA approval for a label expansion of its sleep disorder therapy, Wakix. The approval allows Wakix to be used in children suffering from narcolepsy, a condition marked by extreme daytime sleepiness. This expansion targets a younger patient population for the drug.
Harmony Biosciences Holdings (HRMY) Stock Analysis: A 29.76% Upside Potential Awaits Investors
Harmony Biosciences Holdings (HRMY), a biotechnology company specializing in rare neurological diseases, shows significant investment potential with a 29.76% estimated upside. Its current valuation, robust revenue growth of 28.70%, strong EPS, and substantial free cash flow highlight its financial strength. The company's diverse product pipeline and positive analyst ratings further underscore its promising future in the healthcare sector.
U.S. biopharmaceutical company Harmony Biosciences Holdings, Inc. (Harmony Biosciences) recently announced that its developed drug Wakix® (Pitolisant) has been approved by the U.S. Food and Drug Administration (FDA) for an expanded indication to tr
Harmony Biosciences Holdings, Inc. announced that its drug Wakix® (Pitolisant) received FDA approval for an expanded indication to treat cataplexy in pediatric patients with narcolepsy. This regulatory decision offers a new treatment option for young patients with this rare sleep disorder. The expanded use significantly benefits pediatric patients.
Harmony Biosciences Receives U.S. Food and Drug Administration Approval for WAKIX
Harmony Biosciences announced that the FDA has approved its supplemental new drug application for WAKIX (pitolisant) to treat cataplexy in pediatric narcolepsy patients aged 6 and older. WAKIX is now the first and only FDA-approved non-scheduled treatment for both pediatric and adult narcolepsy patients with or without cataplexy. This approval expands the utility of WAKIX, which was previously approved for excessive daytime sleepiness in adults and pediatric patients, and further solidifies Harmony Biosciences' position in treating rare neurological diseases.
Earnings Preview: Harmony Biosciences Holdings, Inc. (HRMY) Q4 Earnings Expected to Decline
Harmony Biosciences Holdings, Inc. (HRMY) is expected to announce a year-over-year decline in Q4 earnings but higher revenues for the quarter ended December 2025. The company is projected to post quarterly earnings of $0.84 per share on $242.5 million in revenue. However, with a negative Earnings ESP and a Zacks Rank of #1, it's difficult to conclusively predict an earnings beat.
Harmony Biosciences (HRMY) to Release Quarterly Earnings on Tuesday
Harmony Biosciences (NASDAQ:HRMY) is scheduled to release its Q4 2025 earnings before market open on Tuesday, February 24th, 2026. Analysts project earnings of $0.84 per share and revenue of $240.04 million. Despite recent insider selling, the company holds a "Moderate Buy" consensus rating with an average target price of $45.63 from Wall Street analysts.
LSV Asset Management Increases Stake in Harmony Biosciences Holdings, Inc. $HRMY
LSV Asset Management has increased its stake in Harmony Biosciences Holdings, Inc. (HRMY) by 7.1% in the third quarter, now owning 1,594,893 shares valued at approximately $43.96 million. Despite this, insiders, including the CEO and CFO, have sold a total of 50,640 shares worth about $1.93 million over the past 90 days. Analysts maintain a "Moderate Buy" consensus rating for HRMY, with a target price of $45.63.
Understanding Momentum Shifts in (HRMY)
This article analyzes Harmony Biosciences Holdings Inc. (HRMY), highlighting weak near-term sentiment but an exceptional 46.1:1 risk-reward setup. It outlines three AI-generated trading strategies: Long Position, Momentum Breakout, and Risk Hedging, along with multi-timeframe signal analysis. The piece emphasizes the importance of support levels and potential resistance for future price movements.
Wall Street Analysts Believe Harmony Biosciences (HRMY) Could Rally 26.95%: Here's is How to Trade
Harmony Biosciences (HRMY) closed at $36.59, and Wall Street analysts project a mean price target of $46.45, suggesting a 27% upside. This outlook is reinforced by analysts' upward revisions to earnings estimates for the company. While individual price targets can be misleading, the strong agreement among analysts on improved earnings prospects and the company's Zacks Rank #1 (Strong Buy) rating suggest potential for the stock's near-term upside.
A Look At Harmony Biosciences (HRMY) Valuation After Recent Share Price Momentum
Harmony Biosciences (HRMY) has experienced mixed share performance recently, with a modest gain over three months but a decline over the past month. Despite longer-term volatility, the company is considered 18.4% undervalued, with a fair value narrative at $46.45 against a last close of $37.93, based on projections of double-digit top-line growth and rising profitability. This valuation hinges on the successful launch of late-stage pipeline catalysts like ZYN002 and additional pitolisant formulations, aimed at reducing product concentration risk and capturing new revenue.
Harmony Biosciences (NASDAQ:HRMY) Receives "Neutral" Rating from UBS Group
UBS Group has reaffirmed a "neutral" rating on Harmony Biosciences (NASDAQ:HRMY) and increased its price target to $46.00, suggesting a potential upside of over 21%. Despite the "Moderate Buy" consensus among analysts, company insiders have sold over 50,000 shares in the last three months, though they still retain a significant 23.60% ownership. The article also provides a financial overview of Harmony Biosciences and details recent insider trading and institutional investment activity.
Harmony Biosciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
Harmony Biosciences Holdings, Inc. announced it will report its fourth quarter and full year 2025 financial results on Tuesday, February 24, 2026, before the U.S. financial markets open. The company will host a conference call and webcast on the same day at 8:30 a.m. ET to discuss these results. Details for participating in the call and accessing the webcast replay are provided for investors and interested parties.
New York State Common Retirement Fund Acquires 29,501 Shares of Harmony Biosciences Holdings, Inc. $HRMY
The New York State Common Retirement Fund increased its stake in Harmony Biosciences Holdings, Inc. by 43.9% in Q3, adding 29,501 shares to total 96,674 shares valued at approximately $2.66 million. While institutional ownership has grown, company insiders have been net sellers, disposing of over 50,000 shares worth around $1.93 million. Analyst sentiment for Harmony Biosciences remains largely positive, with a consensus "Buy" rating and an average price target of $45.25.
Avoiding Lag: Real-Time Signals in (HRMY) Movement
Harmony Biosciences Holdings Inc. (NASDAQ: HRMY) is exhibiting a mid-channel oscillation pattern with a neutral sentiment across all time horizons, suggesting a wait-and-see approach. The AI analysis identifies an exceptional 42.7:1 risk-reward short setup and provides specific entry, target, and stop-loss levels for position, momentum breakout, and risk hedging strategies. These strategies aim to leverage real-time signals for optimized position sizing and minimized drawdown risk.
Harmony Biosciences Makes The Grade (NASDAQ:HRMY)
Harmony Biosciences (HRMY) is progressing Wakix despite patent challenges and competitive threats, with strong Q3 2025 sales results leading to increased FY25 guidance. The company anticipates multiple late-stage pipeline catalysts in 2026-2027 for rare neurological indications. With a compelling valuation of 9x FY26E EPS, HRMY presents an attractive risk/reward profile, bolstered by its valuation and upcoming clinical milestones.
Is Harmony Biosciences (HRMY) Pricing Reflect Its Cash Flow Potential After Recent Share Weakness
Harmony Biosciences (HRMY) stock has seen recent weakness, but a Simply Wall St valuation suggests it is significantly undervalued. A Discounted Cash Flow (DCF) analysis estimates an intrinsic value of $189.50 per share against a current price of $36.52, implying an 80.7% discount. Furthermore, its P/E ratio of 11.33x is below both the Pharmaceuticals industry average and its proprietary "Fair Ratio," indicating potential undervaluation based on earnings.
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Given Average Recommendation of "Buy" by Analysts
Harmony Biosciences (NASDAQ:HRMY) has received an average "Buy" recommendation from eleven analysts, with an average 12-month price target of $45.25. While company insiders have recently sold shares, institutional ownership is high at 86.23%, and the company reported a revenue beat in its last quarter. Harmony Biosciences is a biopharmaceutical company focused on rare neurological and endocrine diseases, with its flagship product WAKIX, and has a market cap of $2.10 billion.
Capital Management Corp VA Sells 29,654 Shares of Harmony Biosciences Holdings, Inc. $HRMY
Capital Management Corp VA recently reduced its stake in Harmony Biosciences Holdings, Inc. by 8.4% in Q3, selling 29,654 shares and now holding 322,912 shares. Despite insider selling by the CEO and CFO totaling approximately $1.93 million in the last 90 days, institutional ownership remains high at 86.23%, with several major funds increasing their positions. Analysts maintain a consensus "Buy" rating for Harmony Biosciences, with an average price target of $45.25.
Harmony Biosciences CFO Fully Exits Equity Ownership
Harmony Biosciences (HRMY) CFO Sandip Kapadia has fully exited his direct equity ownership, selling 20,961 shares for approximately $752,800. This is the culmination of a series of divestments, though the sale price was slightly below market close. Despite this executive exit, the company has a promising financial outlook, anticipating over $1 billion in revenue from WAKIX by the end of 2026 and maintaining strong analyst ratings for stock price growth.
Insider Sell: Sandip Kapadia Sells Shares of Harmony Biosciences Holdings Inc (HRMY)
Harmony Biosciences Holdings Inc (HRMY) CFO Sandip Kapadia sold 3,746 shares, reducing his holdings to 24,521 shares. This sale is part of a trend over the past year with no insider buys and seven insider sells recorded. The company's stock was trading at $37.15, and GuruFocus assesses it as modestly undervalued with a price-to-GF-Value ratio of 0.78.
Assessing Harmony Biosciences (HRMY) Valuation As Growth, Financial Strength And Technical Signals Attract Investors
Harmony Biosciences (HRMY) is attracting investor interest due to its revenue and earnings growth, strong financial position, and favorable chart patterns. Despite recent share price gains, longer-term shareholder returns have been weaker. The stock is considered undervalued by many analysts, with a fair value of $46.45 compared to its current price of $37.36, driven by growth in sleep and rare disease markets and a promising pipeline.
Harmony Biosciences Holdings, Inc. $HRMY Shares Bought by Universal Beteiligungs und Servicegesellschaft mbH
Universal Beteiligungs und Servicegesellschaft mbH increased its stake in Harmony Biosciences (NASDAQ:HRMY) by 39.3% in the third quarter, now owning 234,779 shares valued at $6.47 million. Other institutional investors like Robeco Institutional Asset Management and Capital Fund Management also acquired new stakes, while Nomura Holdings Inc. and Arrowstreet Capital Limited Partnership significantly boosted their holdings. Harmony Biosciences reported Q3 EPS of $0.87, missing analyst estimates but exceeding revenue expectations, and multiple analysts have recently updated their ratings to "Buy" or "Outperform."
I Was Shocked to Find This Value-Priced Biotech Growth Stock
Harmony Biosciences (NASDAQ: HRMY) is a biotech company specializing in rare neurological disorders, particularly narcolepsy. Its drug, pitolisant (Wakix), is the only FDA-approved narcolepsy treatment not classified as a controlled substance and has seen significant commercial success. Harmony's strong revenue and profits from Wakix allow it to fund an extensive pipeline of new treatments, making it an appealing prospect for value investors in the growth-oriented biotech sector.
Harmony Biosciences (NASDAQ:HRMY) Raised to "Strong-Buy" at Zacks Research
Zacks Research upgraded Harmony Biosciences (NASDAQ:HRMY) from a "hold" to a "strong-buy" rating. The company's stock currently holds an average "Buy" rating from analysts, with a consensus price target of $45.25. Despite recent insider selling by the CFO and CEO, institutional investors show increased interest, and the company has demonstrated strong revenue in its last quarter, although EPS slightly missed expectations.
Harmony’s WAKIX Surges Toward Blockbuster Status as Revenue Nears $1 Billion
Harmony Biosciences (Nasdaq: HRMY) announced preliminary 2025 net product revenue for its narcolepsy drug WAKIX at approximately $868 million, projecting 2026 revenue to reach $1.0 billion to $1.04 billion. The company reported strong fourth-quarter growth and a significant increase in treated patients, indicating WAKIX is on track for blockbuster status. Harmony is also advancing a broad pipeline, including new pitolisant formulations and next-generation therapies, to sustain long-term growth.
Discipline and Rules-Based Execution in HRMY Response
This article provides an AI-driven analysis for Harmony Biosciences Holdings Inc. (NASDAQ: HRMY), highlighting a near-term strong sentiment with neutral mid and long-term outlooks. It identifies a significant short setup with a 44.9:1 risk-reward ratio and outlines specific institutional trading strategies including long, breakout, and short positions with entry, target, and stop-loss levels. The analysis also includes multi-timeframe signal analysis with support and resistance levels.
Harmony Biosciences CFO Kapadia sells $752k in stock
Harmony Biosciences (NASDAQ:HRMY) CFO Sandip Kapadia sold 20,961 shares of common stock for a total of $752,833 on January 15, 2026, executed under a pre-arranged Rule 10b5-1 trading plan. Following this sale, Kapadia directly owns zero shares of the company. Despite the sale, Harmony Biosciences recently reported strong preliminary revenues for WAKIX and announced strategic partnerships and positive Phase 3 trial data for EPX-100, which led H.C. Wainwright to maintain a Buy rating on the stock.
Harmony Biosciences (NASDAQ:HRMY) CFO Sells $752,919.12 in Stock
Harmony Biosciences' (NASDAQ:HRMY) CFO Sandip Kapadia sold 20,961 shares of the company's stock for over $752,919 on January 15th, according to an SEC filing. The stock traded down about 0.9% on elevated volume, with a market cap of $2.07 billion. While the company missed EPS estimates in its last quarterly report, it beat revenue expectations, and analysts maintain a consensus "Moderate Buy" rating with an average target price of $45.25.
Harmony Biosciences CFO Kapadia sells $752k in stock By Investing.com
Harmony Biosciences' CFO, Sandip Kapadia, sold 20,961 shares of common stock for a total of $752,833, leaving him with zero direct ownership. The sale occurred under a pre-arranged trading plan. Despite the sale, InvestingPro analysis suggests the stock is undervalued with strong financial health, and the company recently reported robust revenue growth for WAKIX and promising clinical trial data.
Harmony Biosciences CFO Kapadia sells $752k in stock By Investing.com
Harmony Biosciences CFO Sandip Kapadia sold 20,961 shares of company stock worth $752,833 on January 15, 2026, leaving him with zero direct holdings. This transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Despite the sale, InvestingPro analysis suggests the stock is undervalued with strong financial health, and Harmony Biosciences recently reported positive revenue growth for WAKIX and promising data from clinical trials for other treatments.
Harmony Biosciences projects 2026 WAKIX revenue to exceed $1 billion
Harmony Biosciences (NASDAQ: HRMY) projects WAKIX revenue to exceed $1 billion in 2026, achieving blockbuster status. The company reported preliminary unaudited net product revenue of approximately $243 million for Q4 2025 and $868 million for the full year, a 21% year-over-year increase. Harmony is also advancing new formulations and pipeline candidates, with significant developments in narcolepsy, idiopathic hypersomnia, and rare epilepsies.
Harmony Biosciences Projects WAKIX Revenue to Surpass $1 Billion in 2026
Harmony Biosciences announced preliminary 2025 financial results and issued revenue guidance for 2026, projecting its narcolepsy drug WAKIX to exceed $1 billion in net revenue. The company reported WAKIX's preliminary unaudited net product revenue as approximately $868 million for 2025, and provided 2026 guidance of $1.0 to $1.04 billion. Harmony is also advancing its late-stage pipeline with five Phase 3 trials and developing next-generation pitolisant formulations to extend the franchise, alongside a Phase 1 trial for a novel orexin-2 agonist.
Harmony Biosciences stock drops after ZYN002 exit as 2026 Wakix sales outlook tops $1 billion
Harmony Biosciences (HRMY) shares dropped after the company announced its 2026 sales guidance for Wakix, projecting over $1 billion, while simultaneously discontinuing its ZYN002 Fragile X program. This pipeline reshuffle and revenue outlook sparked investor reaction as healthcare executives gathered for the J.P. Morgan conference. While Wakix is on track for blockbuster status, the exit of ZYN002 closes a potential secondary revenue stream for the company.
HRMY: WAKIX nears blockbuster status as pipeline and commercial expansion drive growth into 2026
Harmony Biosciences (HRMY) is set for significant growth into 2026, primarily driven by WAKIX's trajectory toward blockbuster status. The company benefits from a strong late-stage CNS pipeline and robust financial health, with upcoming milestones including Phase III readouts, NDA submissions, and commercial expansion. These factors provide substantial market opportunity and capital for further development.
Drug for narcolepsy nears blockbuster status as firm runs 5 late-stage trials
Harmony Biosciences announced preliminary 2025 net product revenue of approximately $868 million for WAKIX, a drug for narcolepsy, and projects revenue to exceed $1 billion in 2026, nearing blockbuster status. The company is advancing a robust late-stage pipeline with five ongoing Phase 3 clinical trials for various CNS indications and is working on next-generation pitolisant formulations to extend the drug's franchise into the 2040s. Additionally, Harmony Biosciences is developing an orexin-2 receptor agonist and EPX-100 for Dravet and Lennox-Gastaut syndromes.
Harmony Biosciences Guides to Over $1 Billion in WAKIX® Revenue in 2026; Advancing Robust Late-Stage Pipeline With Potential for Long-term Value Creation
Harmony Biosciences announced preliminary, unaudited net product revenue of approximately $868 million for WAKIX in 2025, projecting it to exceed $1 billion in 2026. The company is advancing a robust late-stage pipeline, including next-generation pitolisant formulations and a potential best-in-class orexin-2 agonist, aiming to extend the pitolisant franchise into the 2040s and drive long-term value creation. Harmony is a profitable, self-funding biotech focused on innovative therapies for rare neurological diseases.
Harmony Biosciences Guides to Over $1 Billion in WAKIX® Revenue in 2026; Advancing Robust Late-Stage Pipeline With Potential for Long-term Value Creation
Harmony Biosciences announced preliminary unaudited net product revenue for WAKIX in 2025 of approximately $868 million, with guidance to exceed $1 billion in 2026. The company is advancing a robust late-stage pipeline, including next-gen pitolisant formulations to extend its franchise into the 2040s and five ongoing Phase 3 registrational clinical trials for various CNS indications. Harmony aims to solidify its position as a profitable, self-funding biotech with strong long-term growth potential.
Harmony Biosciences forecasts WAKIX revenue to exceed $1 billion in 2026
Harmony Biosciences reported preliminary unaudited net product revenue of approximately $868 million for 2025 and projects WAKIX revenue to reach between $1.0 billion and $1.04 billion for 2026. The company saw a 21% increase in revenue from 2024 to 2025 and added approximately 400 WAKIX patients in Q4 2025. Harmony plans a New Drug Application submission for pitolisant GR in Q2 2026, expects Phase 3 data for pitolisant in Prader-Willi syndrome in H2 2026, and initiated a Phase 1 trial for an orexin-2 receptor agonist.
Harmony Biosciences projects 2026 WAKIX revenue to exceed $1 billion By Investing.com
Harmony Biosciences announced preliminary unaudited net product revenue for WAKIX of approximately $243 million for Q4 2025 and $868 million for the full year, representing about 21% year-over-year growth. The company projects WAKIX revenue to exceed $1 billion in 2026, driven by new patient additions and advancements in its pitolisant franchise with new formulations and trials. Harmony also highlighted its undervalued stock, low P/E and PEG ratios, and progress in other pipeline treatments, while discontinuing the ZYN002 program.
Harmony Biosciences Holdings Inc. (HRMY) PT Raised to $37 at Goldman Sachs
Goldman Sachs analyst Corinne Jenkins increased the price target for Harmony Biosciences Holdings Inc. (HRMY) from $35.00 to $37.00. This article notes that the content is premium-only, requiring a subscription to StreetInsider.com for full access.
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) has received a "Moderate Buy" consensus recommendation from analysts, with an average 12-month target price of $45.63. While the company missed quarterly EPS estimates, its revenue exceeded expectations. Insider selling by CEO Jeffrey M. Dayno and significant institutional ownership are also noted.
Assessing Harmony Biosciences (HRMY) Valuation After Fresh Clinical Trial Progress In Rare Neurological Disorders
Harmony Biosciences (HRMY) has seen recent share price momentum following clinical trial progress for its lead drug WAKIX and pipeline candidates targeting rare neurological disorders. Despite a recent 38.37% return over 90 days, the company is considered undervalued with a fair value estimate of US$44.55 compared to its current price of US$36.75. The valuation highlights potential upside from new revenue sources and pipeline catalysts, though challenges like the ZYN-002 Phase 3 setback and future competition for WAKIX exist.
Truist Securities Lowers Price Target for HRMY Amidst Current Buy Rating | HRMY Stock News
Truist Securities has maintained its 'Buy' rating for Harmony Biosciences Holdings (HRMY) but reduced its price target from $48 to $45. This adjustment, led by analyst Danielle Brill, comes amidst varying analyst ratings, with an average target price of $46.18 among 11 analysts, suggesting a potential upside of 22.95% from its current price. Harmony Biosciences focuses on rare neurological diseases, with its key product WAKIX and several pipeline drug candidates.
Harmony Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
Harmony Biosciences Holdings, Inc. announced its participation in the 44th Annual J.P. Morgan Healthcare Conference. Jeffrey M. Dayno, M.D., President and CEO, is scheduled to present on Tuesday, January 13, 2026, at 4:30 p.m. PT / 7:30 p.m. ET. A webcast of the presentation will be available on the investor page of Harmony's website.
Harmony Biosciences Holdings (HRMY) Stock Analysis: A Revenue Growth Powerhouse with 25.66% Upside Potential
Harmony Biosciences Holdings (HRMY) shows strong financial performance with a 28.70% revenue growth and robust free cash flow, driven by its WAKIX product and promising drug pipeline for rare neurological diseases. Analysts project a potential 25.66% upside, indicating a bullish outlook for this biotechnology company, despite its current focus on reinvestment over dividends. The company's strategic focus on R&D for treatments like Pitolisant and ZYN-002 further positions it for long-term expansion and value creation in the biotech sector.
